The mRNA levels of GPRC5D are higher in MM plasma cells than in normal cells (as determined in samples of various tissues from healthy donors), as well as in cells from other hematologic malignancies (e.g., AML, CML, DLBCL, FL, MCL, MGUS, SMM, etc.), which suggests that GPRC5D might represent a potential target for effector-cell-mediated MM therapy [18,19]. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.